Literature DB >> 32578017

Uptake and Usage Patterns of Biosimilar Infliximab in the Medicare Population.

Steven Kozlowski1, Natasha Flowers2, Noy Birger2, Michael Wernecke2, Thomas E MaCurdy2, Jeffrey A Kelman3, David J Graham4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32578017      PMCID： PMC8298739          DOI： 10.1007/s11606-020-05957-1

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN： 0884-8734            Impact factor:   6.473


× No keyword cloud information.
  2 in total

1.  Uptake of the Biologic Filgrastim and Its Biosimilar Product Among the Medicare Population.

Authors:  Steven Kozlowski; Noy Birger; Stephaeno Brereton; Stephen J McKean; Michael Wernecke; Leah Christl; Jeffrey A Kelman
Journal:  JAMA       Date:  2018-09-04       Impact factor: 56.272

2.  Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.

Authors:  Peter C Austin
Journal:  Stat Med       Date:  2009-11-10       Impact factor: 2.373
  2 in total
  3 in total

1.  Physician, Practice, and Patient Characteristics Associated With Biosimilar Use in Medicare Recipients.

Authors:  Emma Boswell Dean; Phyllis Johnson; Amelia M Bond
Journal:  JAMA Netw Open       Date:  2021-01-04

2.  Utilization of Filgrastim and Infliximab Biosimilar Products in Medicare Part D, 2015-2019.

Authors:  S M Qasim Hussaini; Arjun Gupta; Kelly E Anderson; Jeromie M Ballreich; Lauren Hersch Nicholas; G Caleb Alexander
Journal:  JAMA Netw Open       Date:  2022-03-01

3.  Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies.

Authors:  Hillel P Cohen; Sohaib Hachaichi; Wolfram Bodenmueller; Tore K Kvien; Silvio Danese; Andrew Blauvelt
Journal:  BioDrugs       Date:  2022-07-26       Impact factor: 7.744
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.